Belite Bio, Inc
BLTE
Pozycja w akcjach
#3054
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Cena akcji
$148.24
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$5.97B
Zmiana (1 dzień)
3.82%
Zmiana (1 rok)
64.04%
Kraj
US
Handel Belite Bio, Inc (BLTE)
Kategoria
Healthcare
Zyski dla Belite Bio, Inc (BLTE)
Zyski w Jun 2026 TTM: $-102.31M
Według najnowszych raportów finansowych Belite Bio, Inc, obecny zysk firmy wynosi $-102.31M. W roku 2023 firma osiągnęła zysk w wysokości $-31.62M, spadek w porównaniu do zysku z roku 2022, który wynosił $-12.65M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Belite Bio, Inc od 2020 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | $-102.31M | 183.11% |
| 2024 | $-36.14M | 14.28% |
| 2023 | $-31.62M | 150.02% |
| 2022 | $-12.65M | 30.85% |
| 2021 | $-9.67M | 68.05% |
| 2020 | $-5.75M | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | -5,255.85% |
US
|
|
| $-3.09B | 2,917.33% |
US
|
|
| $-4.02B | 3,825.56% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -2,006.63% |
NL
|
